5-Methyl-4-[4-(naphthalen-2-yloxy)-butyl]-1H-imidazole | 524011-96-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-Methyl-4-[4-(naphthalen-2-yloxy)-butyl]-1H-imidazole
• 英文别名: 5-methyl-4-(4-naphthalen-2-yloxybutyl)-1H-imidazole
• CAS: 524011-96-9
• 化学式: C₁₈H₂₀N₂O
• 分子量: 280.37
• InChiKey: HWQASNSWJFAFOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Substituted imidazoles
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20030181479A1

  公开（公告）日：2003-09-25

  The present invention relates to novel substituted imidazoles, to the use of these compounds as medicaments, to pharmaceutical compositions comprising the compounds, and to a method of treatment employing these compounds and compositions. The present compounds show a high and selective binding affinity to the histamine H3 receptor indicating a histamine H3 receptor antagonistic or agonistic activity. As a result, the compounds are useful for the treatment of disorders related to the histamine H3 receptor. More particularly, the present compounds possess a histamine H3 receptor agonistic activity and are accordingly useful in the treatment of disorders in which a histamine H3 receptor activation is beneficial.

  本发明涉及新型取代咪唑，以及这些化合物作为药物的使用，包括含有这些化合物的制药组合物和使用这些化合物和组合物的治疗方法。这些化合物表现出高度选择性的结合亲和力，指示组合物具有组胺H3受体拮抗或激动活性。因此，这些化合物可用于治疗与组胺H3受体有关的疾病。更具体地，这些化合物具有组胺H3受体激动活性，因此可用于治疗组胺H3受体激活有益的疾病。
• PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES
  申请人：NOVO NORDISK A/S

  公开号：EP1446385A1

  公开（公告）日：2004-08-18
• [EN] PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES<br/>[FR] ELABORATION ET UTILISATION D'IMIDAZOLES SUBSTITUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2003040106A1

  公开（公告）日：2003-05-15

  The present invention relates to novel substituted imidazoles, to the use of these compounds as medicaments, to pharmaceutical compositions comprising the com-pounds, and to a method of treatment employing these compounds and compositions. The present compounds show a high and selective binding affinity to the histamine H3 receptor indicating a histamine H3 receptor antagonistic or agonistic io activity. As a result, the compounds are useful for the treatment of disorders related to the histamine H3 receptor. More particularly, the present compounds possess a histamine H3 receptor agonistic activity and are accordingly useful in the treatment of disorders in which a histamine H3 receptor activation is beneficial.